 Deciphera Pharmaceuticals Inc NASDAQ: DCPH stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in patients with gastrointestinal stromal tumor GIST previously treated with Novartis AGs NYSE: NVS Gleevec imatinib. The study did not meet the primary endpoint of improved progression-free survival PFS compared with the standard of care Pfizer Incs NYSE: PFE Sutent sunitinib. 